Bellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by Analysts at

Research analysts at started coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, LADENBURG THALM/SH SH cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 15th.

Bellicum Pharmaceuticals Stock Performance

BLCM opened at $0.80 on Wednesday. Bellicum Pharmaceuticals has a 12 month low of $0.23 and a 12 month high of $1.55. The company has a fifty day simple moving average of $0.45 and a 200 day simple moving average of $0.82.

Institutional Trading of Bellicum Pharmaceuticals

A hedge fund recently bought a new stake in Bellicum Pharmaceuticals stock. HRT Financial LP acquired a new stake in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 36,470 shares of the biopharmaceutical company’s stock, valued at approximately $26,000. HRT Financial LP owned approximately 0.42% of Bellicum Pharmaceuticals as of its most recent SEC filing. 28.66% of the stock is currently owned by hedge funds and other institutional investors.

About Bellicum Pharmaceuticals

(Get Rating)

Bellicum Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time.

Further Reading

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.